Fig. 1
From: Inhibition of RNA-binding proteins enhances immunotherapy in ovarian cancer
C5 tumors exhibit low immune cell infiltration and elevated RBP expression. a Schematic illustrating the classification of HGSC tumor cohorts into molecular subtypes (C1, C2, C4, C5) using GSEA and subtype signatures established by Tothill et al.9 b Pie charts displaying the frequencies (%) and numbers of C5 (blue) and non-C5 (gray) cases in the indicated HGSC-datasets. The analysis platforms and the total number of unambiguously classified cases are provided. TCGA-AC includes additional cases (AC) absent from the TCGA-RNA-Seq cohort. c Bubble chart illustrating enriched (UP) and depleted (DN) gene sets in C5-HGSCs, associated with cancer hallmarks or gene ontology – molecular function (GO: MF) determined by GSEA. Color bars correspond to datasets shown in (b): Sood (black), TCGA-OV-RNA-Seq (purple), Local (blue), AOCS (green), and TCGA-AC (yellow). d scRNA-Seq analysis of HGSC samples. UMAP of 19,151 cells (left) indicates identified tumor and stromal cell clusters. Sample distribution (fraction) and total cluster content (% cells) are presented as bar plots. e Violin blots (left) show cumulative scRNA-seq reads for MHC-I/PD-L1 ratios, CTL activation (IFNG, GZMB, CD69), and exhaustion (CXCL13, HAVCR2, LAYN) associated with immunologically warm (yellow) and cold (blue) cluster. Scatter dot plot (right) indicates reduced MHC-I/PD-L1 ratios of C5-HGSCs. One-way ANOVA testing was used to determine statistical significance. f Scatter plot of the RBP census.22 The top-eight RBPs (oncoRBPs) dysregulated across datasets are highlighted in blue. g UMAPs (left) indicate cumulative scRNA-seq reads for MHC-I (yellow) or oncoRBPs (blue). Scatter dot plot (right) indicates oncoRBP expression in HGSC subtypes. h ROC analysis evaluating the oncoRBP signature (blue) as a classifier for C5 tumors. The C5 signature9 (black) served as a control for comparison
